TABLE 2

Plasma DEHP and MEHP Levels According to Gynecomastia Characteristics and Anthropometric Values

CharacteristicnDEHP Level, mean ± SD, μg/mLMEHP Level, mean ± SD, μg/mL
Mammary gland involved
    Unilateral94.30 ± 1.323.47 ± 1.27
    Bilateral304.77 ± 1.653.11 ± 1.46
1 mammary gland, cm
    <274.18 ± 1.083.14 ± 0.90
    ≥224.71 ± 2.554.63 ± 2.15
Bilateral, cm
    <2155.33 ± 1.623.18 ± 1.31
    ≥2154.22 ± 1.543.03 ± 1.64
Gynecomastia
    With severe pain95.61 ± 1.93a4.14 ± 1.81b
    Without severe pain304.38 ± 1.382.90 ± 1.16
Admitted to the hospital with the complaint of gynecomastia
    Yes184.63 ± 1.923.32 ± 1.61
    No214.70 ± 1.273.07 ± 1.25
Tamoxifen treatment
    Given44.24 ± 2.444.10 ± 2.51
    Not given354.71 ± 1.503.08 ± 1.25
BMI-for-age percentile
    Study group
        1–2495.38 ± 1.583.08 ± 1.34
        25–75174.64 ± 1.493.13 ± 1.66
        76–100134.19 ± 1.533.34 ± 1.18
    Control group
        1–2422.18 ± 1.991.43 (n = 1)
        25–75103.17 ± 0.681.50 ± 0.30
        76–10083.24 ± 0.861.23 ± 0.40